에 대한 최신 뉴스 Boston Scientific (NYSE:BSX) 주식

Boston Scientific

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Stock-Whisper-Index-Logo-6-copy copy

Exclusives

Trading Ideas

MELI

SOFI

UBER

매주, 벤징가의 스톡 위스퍼 지수(Benzinga&#39;s Stock Whisper Index)는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 표면 바로 아래에서 주목을 받을 만한 주식 5종목을 소개한다.

벤징가의 &#39;스톡 위스퍼&#39; 지수: 우버, 보스톤 사이언티픽, EMCOR, 메르카도 리브레 및 소파이

Wall-Street-ai7-1

Analyst Color

Earnings

Equities

Large Cap

Mid Cap

Tech

ETFs

AMGN

AVGO

AZEK

DELL

Janus Henderson Group plc Ordinary Shares

KVYO

MNDY

NVDA

QGEN

SNOW

TOST

UPST

3분기 실적 시즌이 다가오면서, 골드만삭스는 투자자들이 재무 실적을 통해 수익을 올릴 수 있는 주요 주식 기회를 식별한 노트를 발표했다. 애널리스트 존 마샬(John Marshall)과 그의 팀은 목요일에 18개의 주식이 실적 상향 조정의 혜택을 받을 가능성이 있고, 7개의 주식은 하향 조정의 영향을 받을 가능성이 있다고 강조했다.

이번 실적 시즌에 매수할 주식 18개, 매도할 주식 7개: 골드만삭스는 올해를 &#39;주식 선택자의 해&#39;

Tesla's Sky-High Surge

News

Previews

ABBV

AGYS

ASML

BJRI

CHKP

CHTR

CMCSA

DECK

GATX

GOOG

GOOGL

JNPR

NFLX

NXPI

ODFL

ORLY

SKYW

SPOT

TSLA

VRSN

S&amp;P 500 기업들 중 약 14%가 6월 분기 실적을 발표했으며, 더 넓은 지수를 구성하는 기업들의 혼합 실적 성장률은 여전히 ​​양호하다. 이번 주에는 기술 보고 시즌이 공식적으로 시작될 것이며, 이는 최근 주에 가파른 하락세를 보인 시장의 향방을 잠재적으로 결정할 수 있다.

테슬라, 알파벳, GM 및 포드가 이번 주 실적 발표 주도하며 상승세 유지 위해 고군분투

Boston Scientific Corporation Common Stock

Boston Scientific Corp

Basilisk - United States Dollar

BELO SUN MINING CORP ORD by Belo Sun Mining Corp.

Belo Sun Mining Corp

Each week, Benzinga&#8217;s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the <a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">surface and deserve attention</a>.
Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance of information to uncover new opportunities and understand why certain stocks should be of interest.
Read Also:&nbsp;<a href="https://www.benzinga.com/trading-ideas/25/04/44597684/exclusive-marchs-20-most-searched-tickers-on-benzinga-pro-where-do-tesla-nvidia-apple-applovin-stock-rank" target="_blank" rel="noreferrer noopener">EXCLUSIVE: March's 20 Most-Searched Tickers On Benzinga Pro — Where Do Tesla, Nvidia, Apple, Applovin Stock Rank?</a>
Here's a look at the Benzinga Stock Whisper Index for the week ending April 17:
Equinix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>): The data center company saw strong interest from readers during the week. Citigroup recently <a href="https://www.benzinga.com/quote/EQIX/analyst-ratings">maintained a Buy </a>rating on the stock and lowered the price target from $1,020 to $970. Mizuho also lowered the price target from $1,094 to $1,053 recently while maintaining an Outperform rating. All eyes are likely centered on the company's upcoming first-quarter earnings report on April 30. Analysts expect the company to report revenue of $2.22 billion, up from $2.13 billion in last year's first quarter. Analysts expect the company to report quarterly earnings per share of $9.09, up from $8.86 in last year's first quarter. The company has had recent mixed results beating earnings per share in three of the last four quarters, while missing revenue estimates in four straight quarters. The stock was up around 5% over the last five trading sessions, as shown on the<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0417"> Benzinga Pro chart</a> below.
<figure class="wp-block-image size-full"><a href=" https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0417"><img loading="lazy" decoding="async" width="995" height="505" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17174940/Screenshot-379.png" alt="" class="wp-image-877779" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17174940/Screenshot-379.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17174940/Screenshot-379-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17174940/Screenshot-379-768x390.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Prologics Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLD#NYSE">PLD</a>): The industrial and logistics REIT saw strong interest from readers during the week and rejoins the <a href="https://www.benzinga.com/markets/commodities/25/04/44651693/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">Stock Whisper Index.</a> On April 16, the company <a href="https://www.benzinga.com/news/earnings/25/04/44837972/prologis-beats-q1-ffo-estimate-same-store-noi-up-6-2-y-y-more">reported earnings per share </a>of $1.42 that beat a Street consensus estimate of $1.38, while revenue of $2.00 billion missed a Street consensus estimate of $2.04 billion. The company has had mixed recent results, beating earnings per share in fourth straight quarters, while missing revenue estimates from analysts in six straight quarters. Several analysts <a href="https://www.benzinga.com/quote/PLD/analyst-ratings">lowered their price targets </a>on the stock recently. While the quarterly results showed growth, management commentary said that customers were being more cautious given "policy uncertainty." The company reiterated full-year guidance, but the commentary could be something to watch going forward.
<figure class="wp-block-image size-full"><a href=" https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0417"><img loading="lazy" decoding="async" width="991" height="499" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17174955/Screenshot-380.png" alt="" class="wp-image-877780" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17174955/Screenshot-380.png 991w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17174955/Screenshot-380-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17174955/Screenshot-380-768x387.png 768w" sizes="(max-width: 991px) 100vw, 991px" /></a></figure>
Alamos Gold Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGI#NYSE">AGI</a>): Gold stocks continue to be hot with Benzinga readers with Alamos taking its turn on the Stock Whisper Index with gold at <a href="https://www.benzinga.com/news/treasuries/25/04/44857989/gold-nears-3400-mark-experts-point-to-likely-correction-amid-bull-market-rates-will-drop-like-rock">all-time highs</a>. The stock recently got several <a href="https://www.benzinga.com/quote/AGI/analyst-ratings">price target increases</a> from analysts including Scotiabank and RBC Capital. Investors are preparing for the company to report first-quarter financial results on April 30. Analysts expect the company to report revenue of $357.2 million and earnings per share of 23 cents. The company has beaten revenue estimates from analysts in four straight quarters and seven of the last 10 quarters overall. On the earnings side, the company has beaten analyst estimates for EPS in seven of the last 10 quarters overall. Shares are up 98% over the last year and could have more upside from a strong earnings report and positive commentary on how the strong prices of gold are helping the company's future financials.
<figure class="wp-block-image size-full"><a href=" https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0417"><img loading="lazy" decoding="async" width="1001" height="501" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17175012/Screenshot-381.png" alt="" class="wp-image-877781" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17175012/Screenshot-381.png 1001w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17175012/Screenshot-381-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17175012/Screenshot-381-768x384.png 768w" sizes="(max-width: 1001px) 100vw, 1001px" /></a></figure>
Boston Scientific Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>): The medical devices company saw strong interest from readers during the week, which comes ahead of fourth-quarter financial results. The company also received <a href="https://www.benzinga.com/quote/BSX/analyst-ratings">an analyst upgrade</a> from Hold to Buy from Needham with a new price target of $113. Boston Scientific is set to report first-quarter financial results on April 23. Analysts expect the company to report revenue of $4.57 billion, up from $3.86 billion in last year's first quarter. The company has beaten analyst revenue estimates in more than 10 straight quarters. Analysts expect the company to report earnings per share of 67 cents, up from 56 cents per share in last year's first quarter. The company has beaten analyst estimates for earnings per share in eight straight quarters. There are some concerns about<a href="https://www.benzinga.com/general/biotech/25/04/44652075/us-tariffs-spare-drugmakers-but-threaten-diabetes-device-industry"> how tariffs could impact </a>medical devices, but Boston Scientific has remained a strong performer in the sector. The company said 2024 was one of the best years <a href="https://www.benzinga.com/general/health-care/25/02/43494194/boston-scientific-clocks-22-jump-in-q4-sales-on-strong-heart-devices-profit-and-guidance-exceeds-expectations">in its history</a>. Investors will be looking for a strong first quarter and positive commentary to kick things off in 2025.
<figure class="wp-block-image size-full"><a href=" https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0417"><img loading="lazy" decoding="async" width="1001" height="497" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17175026/Screenshot-382.png" alt="" class="wp-image-877784" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17175026/Screenshot-382.png 1001w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17175026/Screenshot-382-300x149.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17175026/Screenshot-382-768x381.png 768w" sizes="(max-width: 1001px) 100vw, 1001px" /></a></figure>
American Express Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>): The credit card company <a href="https://www.benzinga.com/news/earnings/25/04/44862333/american-express-q1-card-spending-strong-ceo-maintains-annual-outlook-contingent-on-economic-climate">reported first-quarter</a> financial results on Thursday with earnings per share of $3.64 beating an analyst estimate of $3.47 and revenue of $16.97 billion beating an analyst estimate of $16.94 billion. The company has beaten analyst estimates for revenue in two straight quarters and for earnings per share in four of the last five quarters. In the earnings results, the company reported strong Card Member spending and higher net interest income. The company said it is seeing steady spending and credit trends despite the macroeconomic concerns. Bank of America recently <a href="https://www.benzinga.com/analyst-ratings/upgrades/25/04/44768565/american-express-receives-upgrade-what-makes-this-stock-so-appealing">upgraded the stock</a> from Neutral to Buy given it high-quality customer base that could keep credit losses in check. During uncertain times, credit card spending could increase and American Express remains a stock to watch with the stock up around 16% over the last year.
<figure class="wp-block-image size-full"><a href=" https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0417"><img loading="lazy" decoding="async" width="995" height="505" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17175041/Screenshot-383.png" alt="" class="wp-image-877785" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17175041/Screenshot-383.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17175041/Screenshot-383-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/17175041/Screenshot-383-768x390.png 768w" sizes="(max-width: 995px) 100vw, 995px" /></a></figure>
Stay tuned for next week&#8217;s report, and follow Benzinga Pro for all the latest headlines and <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0417" target="_blank" rel="noreferrer noopener">top market-moving stories here.</a>
Read the latest Stock Whisper Index reports here:
<ul>
<li><a href="https://www.benzinga.com/25/03/44333602/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noreferrer noopener">March 14</a></li>
<li><a href="https://www.benzinga.com/trading-ideas/25/03/44448522/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-58" target="_blank" rel="noreferrer noopener">March 21</a></li>
<li><a href="https://www.benzinga.com/trading-ideas/25/03/44546189/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-59" target="_blank" rel="noreferrer noopener">March 28</a></li>
<li><a href="https://www.benzinga.com/markets/commodities/25/04/44651693/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">April 4</a></li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/01/43041374/exclusive-how-high-will-sp-500-go-under-donald-trump-in-2025-readers-are-optimistic-26-say-this" target="_blank" rel="noreferrer noopener">EXCLUSIVE: How High Will S&amp;P 500 Go Under Donald Trump In 2025? Readers Are Optimistic, 26% Say This…</a></li>
</ul>

EQIX

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Needham analyst Mike Matson upgraded the rating for Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) from Hold to Buy and announced a $113 price target. Boston Scientific shares closed at $94.23 on Tuesday. <a href="https://www.benzinga.com/quote/BSX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Corey Tarlowe upgraded Grocery Outlet Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GO#NASDAQ">GO</a>) from Hold to Buy and raised the price target from $13 to $18. Grocery Outlet shares closed at $13.90 on Tuesday. <a href="https://www.benzinga.com/quote/GO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Douglas Harter upgraded the rating for UWM Holdings Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UWMC#NYSE">UWMC</a>) from Sell to Neutral but lowered the price target from $4.75 to $4.5. UWM Holdings shares closed at $4.59 on Tuesday. <a href="https://www.benzinga.com/quote/UWMC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Timna Tanners upgraded Freeport-McMoRan Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) from Peer Perform to Outperform and announced a $39 price target. Freeport-McMoRan shares closed at $33.37 on Tuesday. <a href="https://www.benzinga.com/quote/FCX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Redburn Atlantic analyst Oliver Holmes upgraded the rating for Union Pacific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>) from Neutral to Buy and announced a $259 price target. Union Pacific shares closed at $220.08 on Tuesday.  <a href="https://www.benzinga.com/quote/UNP/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying BSX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="588" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16082615/image-6-1024x588.png" alt="" class="wp-image-874216" style="width:589px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16082615/image-6-1024x588.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16082615/image-6-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16082615/image-6-768x441.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/16082615/image-6.png 1075w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/04/44811698/jim-cramer-planet-fitness-is-doing-better-than-expected-says-no-to-this-industrial-stock">Jim Cramer: Planet Fitness Is Doing Better Than Expected, Says No To This Industrial Stock</a> </li>
</ul>
Photo via Shutterstock

Upgrades

Pre-Market Outlook

Markets

Analyst Ratings

UWMC

This Boston Scientific Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

13 analysts have expressed a variety of opinions on Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $118.54, a high estimate of $130.00, and a low estimate of $113.00. This upward trend is evident, with the current average reflecting a 11.31% increase from the previous average price target of $106.50.
<img src="https://www.benzinga.com/files/images/story/2025/1744804893_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Boston Scientific. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Mike Matson &#x7C;Needham &#x7C;Announces &#x7C;Buy &#x7C; $113.00&#x7C;- &#x7C; 
&#x7C;Richard Newitter &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $113.00&#x7C;$120.00 &#x7C; 
&#x7C;Rick Wise &#x7C;Stifel &#x7C;Raises &#x7C;Buy &#x7C; $120.00&#x7C;$115.00 &#x7C; 
&#x7C;Matt Miksic &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $118.00&#x7C;$111.00 &#x7C; 
&#x7C;Danielle Antalffy &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $130.00&#x7C;$105.00 &#x7C; 
&#x7C;Jayson Bedford &#x7C;Raymond James &#x7C;Raises &#x7C;Strong Buy &#x7C; $122.00&#x7C;$119.00 &#x7C; 
&#x7C;Shagun Singh &#x7C;RBC Capital &#x7C;Raises &#x7C;Outperform &#x7C; $116.00&#x7C;$105.00 &#x7C; 
&#x7C;Rick Wise &#x7C;Stifel &#x7C;Raises &#x7C;Buy &#x7C; $115.00&#x7C;$100.00 &#x7C; 
&#x7C;Larry Biegelsen &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $118.00&#x7C;$100.00 &#x7C; 
&#x7C;Joanne Wuensch &#x7C;Citigroup &#x7C;Raises &#x7C;Buy &#x7C; $122.00&#x7C;$107.00 &#x7C; 
&#x7C;Patrick Wood &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $120.00&#x7C;$100.00 &#x7C; 
&#x7C;Matt O'Brien &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $115.00&#x7C;$95.00 &#x7C; 
&#x7C;Jayson Bedford &#x7C;Raymond James &#x7C;Raises &#x7C;Strong Buy &#x7C; $119.00&#x7C;$101.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Boston Scientific. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Boston Scientific compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Boston Scientific's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Boston Scientific's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BSX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Boston Scientific analyst ratings.</a>
<h2>Get to Know Boston Scientific Better</h2>
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
<h3>Boston Scientific: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Boston Scientific's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 22.44%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Boston Scientific's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 12.39%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Boston Scientific's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.66% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.46%, the company showcases effective utilization of assets.
Debt Management: Boston Scientific's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.51.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Boston Scientific Through 13 Analysts

Needham analyst Mike Matson upgrades Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) from Hold to Buy and announces $113 price target.

Price Target

Needham Upgrades Boston Scientific to Buy, Announces $113 Price Target

Truist Securities analyst Richard Newitter maintains Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) with a Buy and lowers the price target from $120 to $113.

Truist Securities Maintains Buy on Boston Scientific, Lowers Price Target to $113

Boston Scientific's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) short percent of float has risen 3.49% since its last report. The company recently reported that it has 13.10 million shares sold short, which is 0.89% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.87 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Boston Scientific Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744297238_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Boston Scientific has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Boston Scientific's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Boston Scientific's peer group average for short interest as a percentage of float is 4.50%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is Boston Scientific Gaining or Losing Market Support?

President Donald Trump announced tougher-than-anticipated tariffs on Wednesday, but there are some <a href="https://www.benzinga.com/topic/tariffs" target="_blank" rel="noreferrer noopener">notable exemptions</a>.
Trump excluded pharmaceuticals from the new tariffs, likely a relief for the industry under pressure following his prior comments suggesting a 25% tariff <a href="https://www.benzinga.com/news/global/25/04/44631606/trumps-tariff-exemptions-include-semiconductors-pharmaceuticals-oil-and-more" target="_blank" rel="noreferrer noopener">on pharmaceutical imports</a>. 
&#8220;The United States can no longer produce enough antibiotics to treat our sick,&#8221; Trump said Wednesday. &#8220;We have a tremendous problem, we have to go to foreign countries to treat our sick. If anything ever happened from a war standpoint, we wouldn&#8217;t be able to do it.&#8221;
The biopharma industry has historically been shielded from tariffs, including during Trump's first term. Investors had feared global tariffs could disrupt the sector, given its significant manufacturing presence in Europe. The Morningstar <a target="_blank" href="https://www.morningstar.com/stocks/biopharma-industry-exempt-global-10-tariff-we-still-see-margin-tax-rate-risks" rel="noreferrer noopener">report</a> says that with the U.S. importing approximately $200 billion in pharmaceuticals in 2024, a 10% tariff could have resulted in a $20 billion cost to the industry, with some of the largest firms facing annual tariffs of up to $1 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44592073/tariffs-could-shake-building-industry-homebuilders-plumbing-flooring-face-rising-costs" rel="noreferrer noopener">Tariffs Could Shake Building Industry: Homebuilders, Plumbing, Flooring Face Rising Costs</a>
Per the Morningstar report on Thursday, a future global tariff on pharmaceuticals remains a risk despite the exemption, potentially pressuring gross margins and long-term tax rates. Companies may need to adjust their manufacturing strategies, though large-cap biopharma firms are expected to maintain strong economic positions. Tariffs could drive near-term margin pressures and lead to long-term U.S. manufacturing investments.
However, new facilities would take years to gain approval, especially with ongoing FDA staff <a href="https://www.benzinga.com/25/04/44634464/despite-headwinds-biotech-sell-off-could-offer-buying-opportunity-bofa" target="_blank" rel="noreferrer noopener">reductions affecting inspections</a>. If U.S. manufacturing increases, corporate tax rates could rise closer to the current 21% rate &#8211; a level Trump aims to maintain through the Republican-controlled Congress.
However, the medical device industry has not been spared, with diabetes device makers appearing to be the hardest hit.
Diabetes device manufacturers, including Dexcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), Insulet Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NYSE">PODD</a>) and Tandem Diabetes Care, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) are among the most affected.
Larger cardiac and orthopedic device makers, such as Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) and Zimmer Biomet Holdings, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBH#NYSE">ZBH</a>) have seen minimal share movement and are expected to shift manufacturing to mitigate tariff effects.
The report <a href="https://www.morningstar.com/stocks/medical-device-industry-swept-up-tariffs-diabetes-device-makers-bear-brunt" target="_blank" rel="noreferrer noopener">notes</a> that among diabetes device makers, Tandem Diabetes appears particularly vulnerable due to its reliance on foreign components and manufacturing, limiting its ability to shift production.
The sector could face further challenges if European competitors, such as Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) and Ypsomed, gain an advantage or if Europe imposes reciprocal tariffs, intensifying competitive pressures.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44647281/fda-approves-amgens-uplizna-as-first-drug-for-chronic-immune-mediated-fibroinflammatory-disorder" target="_blank" rel="noreferrer noopener">FDA Approves Amgen&#8217;s Uplizna As First Drug For Chronic Immune-Mediated Fibroinflammatory Disorder</a></li>
</ul>
Photo: Shutterstock

Biotech

Government

Health Care

General

DXCM

PODD

RHHBY

TNDM

Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry

Looking into the current session, Boston Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) shares are trading at $96.89, after a 3.16% drop. Over the past month, the stock fell by 1.95%, but over the past year, it actually spiked by 44.16%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1743696034_0.png" alt="Past Year Chart" />

<h3>Boston Scientific P/E Compared to Competitors</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Boston Scientific has a lower P/E than the aggregate P/E of 81.19 of the Health Care Equipment &amp; Supplies industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1743696034_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Price Over Earnings Overview: Boston Scientific

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer recommended buying GRAIL, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>), adding that he likes the <a href="https://www.benzinga.com/quote/GRAL">stock a lot.</a>
Supporting his view, Morgan Stanley analyst Tejas Savant, on March 18, raised the price target on the stock from $16 to $20.
&#8220;That' like a dice roll,&#8221; Cramer said when asked about Turkcell Iletisim Hizmetleri A.S. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKC#NYSE">TKC</a>). &#8220;That's a bridge too far for me.&#8221;
On the earnings front, Turkcell, on Feb. 27, posted an FY net profit of 23.52 billion Lira versus a year-ago profit of 18.13 billion Lira.
When asked about Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>), he said, &#8220;I'm going to say buy half right now, and then if it breaks down below 53, then you can buy more.&#8221;
Keefe, Bruyette &amp; Woods analyst Vasundhara Govil, on March 18, upgraded Block from Market Perform to Outperform but lowered the price target from $87 to $80.
Healthpeak Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOC#NYSE">DOC</a>) is a &#8220;reasonable&#8221; REIT, Cramer said.
On Feb. 28, Scotiabank analyst Nicholas Yulico maintained Healthpeak Properties with a Sector Outperform and lowered the price target from $24 to $23.
The Mad Money host said Rubrik, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) is doing &#8220;very, very well.&#8221;
As per the recent news, NTT DATA partnered with Rubrik on Monday for cybersecurity ransomware protection.
Cramer said Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) is a hold and prefers Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) to Edwards Lifesciences.
On the earnings front, Edwards Lifesciences, on Feb. 11, posted better-than-expected quarterly earnings.
&#8220;We have to wait another quarter,&#8221; Cramer said when asked about Shake Shack Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>).
Wells Fargo analyst Anthony Trainor, on Wednesday, initiated coverage on Shake Shack with an Equal-Weight rating and announced a price target of $95.
TransMedics Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) is an &#8220;interesting&#8221; company, Cramer said. &#8220;I'm not going to necessarily recommend it right here.&#8221;
Needham analyst Mike Matson reiterated TransMedics Group with a Hold rating on Wednesday.
&#8220;It's never been this cheap that I can recall,&#8221; Cramer said when asked about Arista Networks Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>). &#8220;Here's the problem, it's a data center stock.&#8221;
On March 5, UBS analyst David Vogt upgraded Arista Networks from Neutral to Buy and raised the price target from $112 to $115.
Price Action:
Turkcell Iletisim Hizmetleri shares fell 2.3% to settle at $6.08 on Thursday.
GRAIL shares gained 0.7% to close at $28.58 during the session.
Arista Networks&#8217; shares fell 3.3% to settle at $78.96.
Shake Shack shares rose 0.3% to settle at $93.62.
TransMedics Group shares gained 0.2% to close at $70.44.
Rubrik shares fell 3.8% to settle at $66.00.
Edwards Lifesciences&#8217; shares rose 0.1% to close at $71.19.
Block shares fell 3.5% to settle at $56.99 on Thursday.
Healthpeak Properties shares fell 0.4% to close at $20.22.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/25/03/44534563/netflix-vertex-pharmaceuticals-and-more-on-cnbcs-final-trades">Netflix, Vertex Pharmaceuticals And More On CNBC&#8217;s &#8216;Final Trades&#8217;</a></li>
</ul>
Photo: Shutterstock

Media

ANET

GRAL

RBRK

SHAK

TMDX

Jim Cramer: Healthpeak Properties Is A 'Reasonable' REIT, Recommends Buying This Health Care Stock

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) has outperformed the market over the past 5 years by 8.22% on an annualized basis producing an average annual return of 25.31%. Currently, Boston Scientific has a market capitalization of $149.09 billion. 
Buying $100 In BSX: If an investor had bought $100 of BSX stock 5 years ago, it would be worth $318.58 today based on a price of $100.80 for BSX at the time of writing.
<h3>Boston Scientific's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743111907_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Boston Scientific 5 Years Ago Would Be Worth This Much Today

Last week,&nbsp;U.S. President&nbsp;Donald Trump vowed to impose a 25% tariff on imported goods from Mexico and Canada and to double tariffs on&nbsp;<a target="_blank" href="https://www.benzinga.com/news/global/25/02/44010093/trumps-plan-for-canada-mexico-china-tariffs-to-start-march-4-could-shake-stock-market" rel="noreferrer noopener">those from China to 20%</a>.
China responded to Trump&#8217;s recent tariff hikes by placing its own tariffs on certain U.S. goods, sanctioning American companies, and planning to file a complaint with&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/25/03/44117288/after-china-mexico-to-hit-back-against-trumps-tariffs-raising-trade-war-risks" rel="noreferrer noopener">the World Trade Organization</a>.
China also banned imports of <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">genetic sequencers</a> from&nbsp;Illumina Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>).
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43706143/why-is-ge-healthcare-stock-trading-higher-on-thursday" rel="noreferrer noopener">Why Is GE HealthCare Stock Trading Soaring On Thursday?</a>
Goldman Sachs has grown more confident that end markets are stabilizing and set for a recovery in 2025, despite ongoing policy and tariff uncertainties. Rising demand and increased stimulus are helping ease market bottlenecks.
Following a visit to China, Goldman Sachs analysts see capital equipment markets at a turning point and write that innovation remains a key advantage.
They are also optimistic about GE Healthcare Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) and Boston Scientific Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) in the region.
While Intuitive Surgical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) offers unique technology, economic constraints, and national quotas may limit its growth. Meanwhile, local competition is expanding quickly, but Goldman Sachs sees limited impact due to a lack of technological differentiation. As a result, analyst David Roman upgraded GE Healthcare stock from Neutral to Buy, raising the <a target="_blank" href="https://editorial.benzinga.com/wp-admin/post.php?post=819159&amp;action=edit" rel="noreferrer noopener">price target from $85 to $100</a>.
The analyst has a balanced view on GE Healthcare with stable 4-5% growth in the base business (ex-China), offset by sustained headwinds in the China business (~14% of sales), which would yield top-line growth below consensus and the company&#8217;s medium targets of 4-6% organic revenue growth.
The forecast increase is due to stabilizing trends in China. The analyst expects China sales to return to 2023 levels by 2026, unlike the previous forecast, which did not anticipate a rebound through 2028.
Price Action: GEHC stock is up 0.45% at $85.74&nbsp;at the last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44251506/inuvo-is-better-aligned-with-consumer-demand-for-privacy-new-regulations-analyst" target="_blank" rel="noreferrer noopener">Inuvo Is Better Aligned With Consumer Demand For Privacy, New Regulations: Analyst</a></li>
</ul>
Photo by PixelBiss via Shutterstock

GEHC

ILMN

ISRG

Goldman Sachs Gains Confidence In Market Rebound, Upgrades GE Healthcare Amid China Recovery Hopes

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) has outperformed the market over the past 5 years by 9.97% on an annualized basis producing an average annual return of 28.2%. Currently, Boston Scientific has a market capitalization of $140.77 billion. 
Buying $1000 In BSX: If an investor had bought $1000 of BSX stock 5 years ago, it would be worth $2,951.28 today based on a price of $95.39 for BSX at the time of writing.
<h3>Boston Scientific's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741706110_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Watching Boston Scientific Corp; Hearing Investor Business Daily SwingTrader Buys Stock

In the preceding three months, 17 analysts have released ratings for Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">10</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Boston Scientific, presenting an average target of $114.88, a high estimate of $130.00, and a low estimate of $100.00. Surpassing the previous average price target of $103.06, the current average has increased by 11.47%.
<img src="https://www.benzinga.com/files/images/story/2025/1741024862_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of Boston Scientific by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$118.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$122.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$116.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$118.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$122.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$115.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$119.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Joshua Jennings</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$107.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$101.00</td>
<td>$98.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Boston Scientific. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Boston Scientific compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Boston Scientific's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BSX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Boston Scientific analyst ratings.</a>
<h2>Get to Know Boston Scientific Better</h2>
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
<h3>Financial Insights: Boston Scientific</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Boston Scientific showcased positive performance, achieving a revenue growth rate of 22.44% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Boston Scientific's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 12.39% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.66%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Boston Scientific's ROA stands out, surpassing industry averages. With an impressive ROA of 1.46%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.51.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 17 Analysts Discuss Boston Scientific Stock

On Monday, Boston Scientific Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) agreed to acquire SoniVie Ltd., a privately held medical device company that has developed the TIVUS <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44073224/boston-scientific-announces-agreement-to-acquire-sonivie-ltd" rel="noreferrer noopener">Intravascular Ultrasound System</a>.
Boston Scientific currently holds an equity stake of approximately 10%. Therefore, the transaction consists of an upfront payment of approximately&nbsp;$360 million&nbsp;for the 90% and up to&nbsp;$180 million&nbsp;upon achievement of a regulatory milestone.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43494194/boston-scientific-clocks-22-jump-in-q4-sales-on-strong-heart-devices-profit-and-guidance-exceeds-expectations" rel="noreferrer noopener">Boston Scientific Clocks 22% Jump In Q4 Sales On Strong Heart Devices, Profit And Guidance Exceeds Expectations</a>
On a 100% basis, the transaction price consists of $400&nbsp;million upfront and up to&nbsp;$200 million upon achievement of a regulatory milestone.
An investigational TIVUS system is designed to denervate nerves surrounding blood vessels to treat a variety of hypertensive disorders, including renal artery denervation (RDN) for hypertension.
Boston Scientific anticipates completing the transaction in the first half of 2025.
The company expects the transaction to be slightly dilutive to adjusted EPS in 2025.
The TIVUS system is designed to perform RDN that can help reduce activity in the kidney&#8217;s renal nerves and serve as an alternative or adjunctive therapy to these medications to help regulate blood pressure.
Compared to radiofrequency energy, ultrasound energy has the potential to penetrate the tissue more deeply, which may result in faster procedures with effective nerve ablation.
The catheter-based TIVUS system generates precise ultrasound energy that passes through the blood and into renal arteries, supplying blood to the kidneys without anchoring to the artery wall, allowing continual blood flow to cool the treatment area.
This energy is designed to heat and ablate the bundles of nerves outside the arteries, stopping their ability to pass signals and reducing the sympathetic hormones released from the nerves. As a result, the blood vessels relax, and the pressure within them is reduced.
Last year, SoniVie announced efficacy data from an IDE pilot trial of the TIVUS system in the U.S. and&nbsp;Israel. The company recently initiated the THRIVE global IDE pivotal trial of the device.
Price Action: BSX stock is up 0.97% at $104.88 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/02/44053788/alkami-growth-accelerates-with-mantl-deal-boosting-digital-banking-and-cross-sell-potential-analyst-says" target="_blank" rel="noreferrer noopener">Alkami Growth Accelerates With MANTL Deal, Boosts Digital Banking And Cross-Sell Potential: Analyst</a></li>
</ul>
Photo: Shutterstock

Boston Scientific To Acquire SoniVie For $400 Million, Expanding Hypertension Treatment Portfolio

Needham analyst Mike Matson reiterates Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Boston Scientificto Hold

An investigational technology, the TIVUS system is designed to denervate nerves surrounding blood vessels to treat a variety of hypertensive disorders, including renal artery denervation (RDN) for hypertension.

Boston Scientific Agreed To Acquire SoniVie, A Privately Held Medical Device Company That Has Developed The Tivus Intravascular Ultrasound System For Approximately $360M And Up To $180M Upon Achievement Of A Regulatory Milestone

Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) has outperformed the market over the past 10 years by 8.74% on an annualized basis producing an average annual return of 19.64%. Currently, Boston Scientific has a market capitalization of $148.32 billion. 
Buying $1000 In BSX: If an investor had bought $1000 of BSX stock 10 years ago, it would be worth $5,903.87 today based on a price of $100.50 for BSX at the time of writing.
<h3>Boston Scientific's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740522627_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Boston Scientific 10 Years Ago Would Be Worth This Much Today

Boston Scientific's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>) short percent of float has fallen 27.55% since its last report. The company recently reported that it has 10.45 million shares sold short, which is 0.71% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.65 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Boston Scientific Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740407417_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Boston Scientific has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Boston Scientific's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Boston Scientific's peer group average for short interest as a percentage of float is 3.93%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

What Does the Market Think About Boston Scientific?

Reported Friday, Boston Scientific Prices €1.5B In Senior Notes, Consisting Of €850M 3.000% Due 2031 And €650M 3.250% Due 2034

Press Releases

Biotech Breakthroughs: Sana Biotechnology (NASDAQ: SANA) Type 1 Diabetes, CS Diagnostics (OTCQB: CSDX) Cancer Therapy – CURR, TPET, PRSO, PNPN.V, EONR – Plus More Stocks Under $2 Inside See Now!

Late-breaking data presented at AF Symposium 2025 highlight key Boston Scientific therapies for management of patients with atrial fibrillation

Boston Scientific announces results for fourth quarter and full year 2024

Boston Scientific to participate in TD Cowen's 45th Annual Health Care Conference

UroGen Pharma Ltd. (NASDAQ: URGN), CS Diagnostics Corp. (OTCQB: CSDX) and Boston Scientific (NYSE: BSX) Advancing Cancer Treatment Technology – More Stocks Inside

Offerings

Boston Scientific announces pricing of €1.5 billion of senior notes

Boston Scientific announces completion of €1.5 billion offering of senior notes

Boston Scientific announces agreement to acquire SoniVie Ltd.

Boston Scientific announces conference call discussing first quarter 2025 results

Nalu Medical Appoints Veteran Medtech Executive Raymond W. Cohen Chairman of its Board of Directors

ACHR

CSDX

CURR

CYCU

IQST

JOBY

KMTS

ONDS

PNPNF

PRSO

RSLS

SANA

SINT

TPET

TRNR

TRUG

TSXV:PNPN

UMAC

URGN

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings

Needham

Truist Securities

Stifel

Barclays

매주, 벤징가의 스톡 위스퍼 지수(Benzinga's Stock Whisper Index)는 독점 데이터(proprietary data)와 패턴 인식의 조합을 사용하여 <a href="https://www.benzinga.com/topic/stock-whisper-index" target="_blank" rel="noreferrer noopener">표면 바로 아래에서 주목</a>을 받을 만한 주식 5종목을 소개한다.
투자자들은 가치가 저평가된, 관심이 적은, 새로운 주식들을 항상 찾고 있다. 소매 거래자들이 사용할 수 있는 방법은 무수히 많기 때문에 새로운 기회를 발견하고 특정 주식이 관심을 가져야 하는 이유를 이해하기 위해 풍부한 정보를 조사하는 것이 어려운 경우가 많다.
또한 읽기: <a href="https://kr.benzinga.com/news/usa/stocks/%EB%8F%85%EC%A0%90-2024%EB%85%84-12%EC%9B%94-%EB%B2%A4%EC%A7%95%EA%B0%80-%ED%94%84%EB%A1%9C%EC%97%90%EC%84%9C-%EA%B0%80%EC%9E%A5-%EB%A7%8E%EC%9D%B4-%EA%B2%80%EC%83%89%EB%90%9C-%EC%83%81%EC%9C%84-20/" target="_blank" rel="noopener">독점: 2024년 12월 벤징가 프로에서 가장 많이 검색된 상위 20개 티커 – 테슬라, 엔비디아, 양자 컴퓨팅 주식은?</a>
<h4 class="wp-block-heading">다음은 1월 3일로 끝나는 주간의 벤징가 ‘스톡 위스퍼' 지수의 개요:</h4>
1. 우버 테크놀로지스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>):
이 차량 공유 회사는 지난주 동안 큰 관심을 보였으며 골드만삭스가 해당 주식을 &#8216;컨빅션 리스트&#8217;에 <a href="https://kr.benzinga.com/news/usa/stocks/%EA%B3%A8%EB%93%9C%EB%A7%8C%EC%82%AD%EC%8A%A4-%EC%BB%A8%EB%B9%85%EC%85%98-%EB%A6%AC%EC%8A%A4%ED%8A%B8%EC%97%90-3%EA%B0%9C%EC%9D%98-%EC%A3%BC%EC%8B%9D-%EC%B6%94%EA%B0%80-%EB%B0%8F-2025%EB%85%84/" target="_blank" rel="noopener">추가하면서</a> 새해를 시작했다. 애널리스트 에릭 셰리던(Eric Sheridan)은 앞으로 2년간 우버의 강력한 복합 연 성장과 조정된 EBITDA를 전망하며, 목표 주가를 $96로 설정했다. 경쟁사인 리프트(Lyft)가 인수에 관심을 보일 수 있다고 디 인포메이션(The Information)이 예측하여 우버가 2025년에 큰 관심을 보일 수도 있다.
우버의 주가는 금요일 2.25% 상승한 $64.59에 마감되었다. 지난 5거래일 동안 5.45% 상승했으며, 지난 1년 동안 11.75% 상승했다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03162855/Screenshot-284.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
2. 보스톤 사이언티픽 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>):
이 의료 기기 회사는 3월 이후 <a href="https://www.benzinga.com/exclusives/24/03/37894121/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet" target="_blank" rel="noopener" data-google-interstitial="false">다시 스톡 위스퍼</a> 지에 등장했다. 주가는 52주 최고가 근처에서 거래되고 있으며, 애널리스트들은 <a href="https://www.benzinga.com/quote/BSX/analyst-ratings" target="_blank" rel="noopener" data-google-interstitial="false">목표 주가</a>를 계속해서 올리고 있다. 에버코어는 목표 주가를 $95에서 $100으로, BITG는 $97에서 $101으로 상향 조정했다. 이 회사는 1월 13일 JP모건 헬스케어 컨퍼런스에서 발표할 예정이다. 2025년의 더 많은 업데이트와 촉매제를 제공할 수 있다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03162929/Screenshot-285.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
3. EMCOR 그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EME#NYSE">EME</a>):
이 건설 및 시설 서비스 회사는 최근 뉴스가 제한적임에도 불구하고 투자자들로부터 강한 관심을 받았다. 2025년 건설 및 사업 지출이 성장 분야가 될 것으로 예상되면서 투자자들의 레이더에 오를 수 있다. EMCOR는 에이미 달(Amy Dahl)이 회사 이사회에 <a href="https://www.businesswire.com/news/home/20241219066760/en/Amy-E.-Dahl-Elected-to-the-EMCOR-Group-Inc.-Board-of-Directors" target="_blank" rel="noopener">임명</a>되었다는 최근 발표로 인해 관심이 높아질 수도 있다. 달은 토로 컴퍼니(The Toro Company)의 국제 비즈니스 및 전략 부문 부사장으로 재직하고 있으며 야외 잔디 및 조경 유지 관리에 대한 그녀의 전문 지식은 새로운 비즈니스 부문에서 EMCOR에 도움이 될 수 있다.
EMCOR의 주가는 금요일 3.50% 상승한 $473.65에 마감되었다. 지난 1년 동안 120% 이상 상승했다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03162943/Screenshot-286.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
4. 메르카도 리브레 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>):
이 라틴 아메리카 전자상거래 회사는 지난주 강한 독자 관심을 받았으며, 투자자들이 새로운 백악관 행정부 하에서 이익을 얻을 수 있는 국가에 대한 투자를 모색하거나 인구 및 소득 수준이 증가하는 국가에 대한 노출을 모색하고 있기 때문에 앞으로의 주제가 될 수 있다. 이 회사는 전자상거래, 운송, 물류, 광고, 핀테크 등 여러 부문에 걸쳐 사업을 운영하고 있으며 여러 국가에서 사업을 운영하고 있다. 해당 주식은 최근 <a href="https://www.benzinga.com/trading-ideas/24/12/42628286/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-including-qubt-qbts" target="_blank" rel="noopener" data-google-interstitial="false">12월에</a> 이름에 대한 높은 관심을 받으며 스톡 위스퍼 지수에 등재되었다. 이 회사의 3분기 매출은 8분기 연속 분석가 추정치를 상회했다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03163001/Screenshot-287.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
5. 소파이 테크놀로지스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>):
이 금융 서비스 주식은 지난주 독자들 사이에서 큰 관심을 보였으며 계속해서 개인 투자자들 사이에서 인기 있는 주식으로 자리매김하고 있다. 키프, 브루옛 &amp; 우즈(Keefe, Bruyette and Woods)는 주가를 시장 성과에서 언더퍼폼(Underperform)으로 <a href="https://www.benzinga.com/quote/SOFI/analyst-ratings" target="_blank" rel="noopener" data-google-interstitial="false">하향 조정</a>하고 목표 주가를 $7에서 $8로 높였다. 이 분석가는 가치 평가에 대한 <a href="https://www.benzinga.com/general/market-summary/25/01/42762341/sofi-tech-downgraded-over-valuation-concerns-stock-priced-three-times-its-peers" target="_blank" rel="noopener" data-google-interstitial="false">우려</a>와 장기적인 수익 잠재력 부족을 언급했다. 낮은 금리는 주식을 보는 투자자들에게 낙관론을 제공할 수 있다. 주식이 투자자들의 관심을 끌 수 있는 또 다른 이유는 회사의 학자금 대출 부문이다. 도널드 트럼프가 백악관으로 복귀함에 따라 조 바이든 대통령의 <a href="https://www.benzinga.com/24/12/42673338/biden-dumps-student-loan-forgiveness-plans" target="_blank" rel="noopener" data-google-interstitial="false">학자금 대출 탕감 프로그램</a>이 종료될 수도 있다.
소파이의 주가는 금요일 5.02% 상승한 $14.84에 마감되었다. 지난 5거래일 동안 9.62% 하락했지만, 지난해에는 70% 이상 상승했다.
<img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/03163018/Screenshot-288.png?optimize=medium&amp;dpr=1.25&amp;auto=webp&amp;width=2048" />
다음 주 보고서를 계속 지켜봐 주시기 바랍니다. <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent111524&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">여기에서</a> Benzinga Pro를 팔로우하여 모든 최신 헤드라인과 시장을 움직이는 주요 기사를 확인하세요.
여기에서 최근 ‘스톡 위스퍼 지수' 보고서를 읽어보세요.
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%A4%EC%A7%95%EA%B0%80%EC%9D%98-%EC%8A%A4%ED%86%A1-%EC%9C%84%EC%8A%A4%ED%8D%BC-%EC%A7%80%EC%88%98-%EC%8B%A4%EC%8A%A4%ED%81%AC-%EB%A6%AC%EC%A0%9C%ED%8B%B0-%EC%BB%B4%ED%93%A8/" target="_blank" rel="noopener">12월 28일</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%A4%EC%A7%95%EA%B0%80%EC%9D%98-%EC%8A%A4%ED%86%A1-%EC%9C%84%EC%8A%A4%ED%8D%BC-%EC%A7%80%EC%88%98-d-%EC%9B%A8%EC%9D%B4%EB%B8%8C-%ED%80%80%ED%85%80-%EC%BB%B4%ED%93%A8%ED%8C%85-%EC%82%AC/" target="_blank" rel="noopener">12월 21일</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%A4%EC%A7%95%EA%B0%80%EC%9D%98-%EC%8A%A4%ED%86%A1-%EC%9C%84%EC%8A%A4%ED%8D%BC-%EC%A7%80%EC%88%98-%EC%8A%A4%EB%83%85-%EC%8B%A4%EC%8A%A4q-%EB%B2%84%ED%8B%B0%EB%B8%8C/" target="_blank" rel="noopener">12월 14일</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%B2%A4%EC%A7%95%EA%B0%80%EC%9D%98-%EC%8A%A4%ED%86%A1-%EC%9C%84%EC%8A%A4%ED%8D%BC-%EC%A7%80%EC%88%98-%ED%94%84%EB%A1%9C%ED%83%80%EB%9D%BC-%EB%A7%88%EB%9D%BC-%ED%8A%B8%EB%A0%88/" target="_blank" rel="noopener">12월 7일</a></li>
</ul>
다음 읽기:
<ul class="block core-block">
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%96%91%EC%9E%90-%EC%BB%B4%ED%93%A8%ED%8C%85-%EC%83%88%EB%A1%9C%EC%9A%B4-ai-2025%EB%85%84%EC%97%90-%EB%B9%A0%EB%A5%B4%EA%B2%8C-%ED%99%95%EC%9E%A5%EB%90%98%EB%8A%94-%EC%8B%9C%EC%9E%A5-%EB%B0%8F/" target="_blank" rel="noopener">양자 컴퓨팅: 새로운 AI? 2025년에 빠르게 확장되는 시장 및 상위 주식 살펴보기</a></li>
</ul>
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

벤징가의 '스톡 위스퍼' 지수: 우버, 보스톤 사이언티픽, EMCOR, 메르카도 리브레 및 소파이

Comments

Boston Scientific

뉴스

에 대한 최신 뉴스 Boston Scientific (NYSE:BSX) 주식

토요일, 1월 04, 2025

금요일, 10월 11, 2024

일요일, 7월 21, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌